CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that CytRx President and CEO Steven A. Kriegsman and Chief Medical Officer Daniel Levitt, M.D., Ph.D., will present at the Rodman & Renshaw Annual Global Investment Conference being held at the Grosvenor House Hotel in London on Monday, May 17, at 2:25 p.m. local time (9:25 a.m. Eastern time). The presentation will include a discussion of the Company's clinical development plans for its high-value oncology development pipeline, including up to six Phase 2 oncology clinical trials in 2010. A live webcast of the presentation will be available on the Company's Web site at www.cytrx.com, and a replay will be available for 90 days.

About CytRx

CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The CytRx oncology pipeline includes three programs in clinical development for cancer indications, including INNO-206, bafetinib and tamibarotene. CytRx recently announced plans to initiate Phase 2 clinical trials with its oncology candidate INNO-206 as a treatment for pancreatic cancer, gastric cancer and soft tissue sarcomas. The Company also has announced plans to initiate three Phase 2 clinical trials with bafetinib as a treatment for high-risk B-cell chronic lymphocytic leukemia (B-CLL), glioblastoma multiforme (a common and aggressive type of primary brain tumor) and advanced prostate cancer. In addition, CytRx is developing two drug candidates based on its industry-leading molecular chaperone technology, which aims to repair or degrade misfolded proteins associated with disease. CytRx also maintains a 28% equity interest in publicly traded RXi Pharmaceuticals, Inc. (NASDAQ: RXII). For more information on the Company, visit www.cytrx.com.

Copyright Business Wire 2010